Erythropoiesis News and Research

RSS

Ago2 and hematopoiesis

Argonaute 2 (Ago2) is unique among its family: It is the only one of the four mammalian Argonaute proteins that exhibits endonuclease 'slicer' activity (facilitation of miRNA-guided cleavage of target mRNA).

12 Jul 2007

Caution against over-aggressive use of erythropoiesis-stimulating agents for cancer-related anemia

Echoing recent FDA warnings, a research group from Northern Ireland cautions against over-aggressive use of a group of drugs called "erythropoiesis-stimulating agents" (ESAs) to treat anemia in some cancer patients, according to a commentary in the April issue of The Oncologist, published by AlphaMed Press.

1 May 2007

Anemia treatment for patients with kidney disease can differ by dialysis facility type

Large, for-profit dialysis facilities appear to administer higher than necessary amounts of a medication for treating anemia in patients with kidney disease, compared to nonprofit facilities, according to a study in the April 18 issue of JAMA.

18 Apr 2007

FDA strengthens safety information for Erythropoiesis-Stimulating Agents (ESAs)

The U.S. Food and Drug Administration (FDA) has issued a public health advisory outlining new safety information, including revised product labeling about erythropoiesis-stimulating agents (ESAs), widely-used drugs for the treatment of anemia.

11 Mar 2007

Mechanism driving iron overload in thalassemia identified

Led by researchers at Weill Cornell Medical College in New York City, an international group of scientists has pinpointed a specific genetic relationship as the cause of dangerous iron overload in persons with a form of the inherited blood disease, beta-thalassemia.

14 Feb 2007

Affymax and Takeda announce agreement for commercialization of Hematide for anemia

Affymax and Takeda Pharmaceutical Company have announced that the companies have entered into an exclusive global agreement to develop and commercialize Affymax's lead product candidate, Hematide, for the treatment of anemia.

27 Jun 2006

First ever study in hemodialysis patients to show stable hemoglobin levels

New data confirm that subcutaneous injection of the innovative new anti-anemia agent CERA (Continuous Erythropoietin Receptor Activator) delivers rapid, sustained and stable correction of anemia in a broad spectrum of patients with chronic kidney disease at dosing intervals of up to 4 weeks.

1 Nov 2004

Common anemia drug may protect hearts of infants undergoing surgical repair of congenital defects

Medical College of Wisconsin researchers may have promising news for the many infants who are born with a congenital heart defect serious enough to require surgery before their first birthday.

21 Apr 2004

Erythropoiesis News and Research

Ago2 and hematopoiesis

Caution against over-aggressive use of erythropoiesis-stimulating agents for cancer-related anemia

Anemia treatment for patients with kidney disease can differ by dialysis facility type

FDA strengthens safety information for Erythropoiesis-Stimulating Agents (ESAs)

Mechanism driving iron overload in thalassemia identified

Affymax and Takeda announce agreement for commercialization of Hematide for anemia

First ever study in hemodialysis patients to show stable hemoglobin levels

Common anemia drug may protect hearts of infants undergoing surgical repair of congenital defects

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News